Live
FierceBiotechBioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor typesFierceBiotechIdeaya sees clear path to FDA as Servier-partnered eye cancer drug hits goal in phase 2/3 trialFierceBiotechSeaport, Hemab prepare for IPO voyages to fund depression, clotting candidatesFierceBiotechRegeneron rides into radiopharma via $2.1B biobucks pact with Australia’s TelixFierceBiotechAllogene’s off-the-shelf CAR-T erases lingering lymphoma cells in early slice of dataEndpoints NewsIdeaya’s uveal melanoma drug exceeds success benchmark in late-stage trialLonza NewsBiologics Contract Manufacturing Market to Hit US$ 83.47 - openPR.comThermo FisherGoldman Sachs Adjusts PT on Thermo Fisher Scientific to $610 From $650, Maintains Buy Rating - marketscreener.comPharmaVoicePredictive analytics in pharma turns lab data into launch strategiesBioPharma DiveRethinking dermatology trial design for late-stage successBioPharma DiveConnected medical devices: Smarter care starts hereEndpoints NewsSeaport and Hemab file for IPOs, with Kailera expected to price soon
FierceBiotech Apr 13, 2026

Seaport, Hemab prepare for IPO voyages to fund depression, clotting candidates

Seaport, Hemab prepare for IPO voyages to fund depression, clotting candidates

Original
Body unavailable. Use the original source.

Directory

59 All